A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2017
This article has no abstract
Epistemonikos ID: bac4fa4902195990695b95de7bb44db5aba672d5
First added on: Apr 16, 2025